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1. Introduction 
A basic underlying propensity of the central nervous system is the capacity to change. 
Neuroplasticity refers to the adaptive capacity of the brain to undergo alteration of 
structural organization and functioning in response to environmental change [1]. While this 
appears to be a very useful process, potential extremes of such plasticity can result in 
various forms of neurological and neuropsychiatric anomalies. Therefore, it appears that the 
same mechanisms that are important in adaptive activity, like learning and memory, can 
provide the basis for abnormal discharge. This being the case, how is it that the normal 
healthy brain becomes transformed into an abnormal brain? Neuroscientists use animal 
models to help them uncover the underlying neural mechanisms. 
While animal research has revealed extensive information on the cellular, synaptic, and 
pathological mechanisms of neurological and neuropsychiatric processes, many 
unanswered questions remain. For instance, there is no neuropsychiatric disorder that is 
adequately understood from the level of clinical manifestations to the underlying cellular 
and molecular mechanisms. Because of the ethical barriers to using humans and the 
inherent limitations of using excised human tissue, inquiry into neurological and 
neuropsychiatric disorders has necessarily relied upon experimental models. For example, 
in vivo animal models have been indispensable for the testing of anticonvulsant drugs, for 
determining some of the basic mechanisms of seizure expression, and for determining 
changes in functional and morphological properties [2-4]. 
Animal models have been, and will continue to be invaluable for: 1) modeling the clinical 
condition, 2) determining the basic mechanisms underlying the genesis and progression of 
the disease, and 3) screening potential pharmacological agents. While an ideal model would 
possess properties identical to all aspects of the particular human condition, this is most 
likely unattainable. The characteristics of a valuable model should possess a substantial 
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degree of similarity to, at least some aspect, of the disorder of interest [5,6]. Accordingly, a 
good animal model should be able to provide new understanding into the disorder it 
models and respond in a reproducible and predictable manner. For example, the kindling 
model, depending on the animal species, possesses many of these characteristics and is an 
excellent model for certain clinical disorders, their underlying mechanisms, and as a 
screening tool for newer pharmacological agents [3,4].  
An understanding of the brain circuitry that underlies normal and adaptive behaviors 
provides a foundation for clarifying the pathology and pathophysiology of psychiatric 
disorders. The key structures and pathways associated with abnormal behaviors have been 
framed through a weighty historical record of anatomical observations. Neuroscience has 
been gradually unveiling the neural networks that subserve the functional domains of 
motivation, emotion, and cognition, central tenets to psychiatry. The convergence of 
findings from the multiplicity of research methods and techniques across both animal and 
human studies has provided the neurocircuitry framework pertinent to neurological and 
neuropsychiatric diseases. 
A brain structure that receives substantial scientific interest today is the amygdala. The 
amygdalae are a group of nuclei located deep within the medial temporal lobe of the brain 
[7]. It has a wide range of connections with other brain regions, allowing it to participate in a 
wide variety of behavioral functions. Considered to be part of the limbic system, the 
amygdala performs an important role in the processing and memory of emotional reactions. 
Structural and functional changes within the amygdala are associated with a broad range of 
psychiatric conditions in humans, such as anxiety disorders [8], depression [9], 
schizophrenia [10], and autism [11]. 
This chapter will review the various experimental models employed to gain insight into the 
underlying mechanisms of key neurological and neuropsychiatric disease states, with a 
focus on the amygdalae. In particular, this chapter will examine models of brain plasticity, 
models of epilepsy, fear and anxiety, affective disorders, neurodevelopmental disorders, 
and neurodegenerative disorders. 
2. The amygdala 
The amygdaloid complex is a large subcortical structure located in the rostromedial part of 
the temporal lobe in front of the hippocampus and underneath the uncus of the 
parahippocampal gyrus (i.e., entorhinal cortex). Some of the most prominent pathways to 
the amygdaloid complex come from cortical areas in the temporal and frontal lobes. Its 
components are morphologically and histochemically heterogenous, as are its functions and 
connections with other brain regions [12]. The amygdala has close interconnections with 
both cortical and subcortical areas. The cortical areas include temporal (perirhinal and 
entorhinal), frontal, insular, and cingulate association areas and the subcortical areas include 
brainstem, hypothalamus, thalamus, hippocampus, and claustrum [12,13].  
The many components of the amygdaloid complex can be grouped into three principal 
divisions: the basolateral, cortical, and centromedial nuclear groups. The largest part of the 
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amygdala is the basolateral nuclear group. It is closely related to many cortical areas in the 
prefrontal, temporal, insular, and occipital regions and is reciprocally connected to them. 
The basolateral amygdala projects to the striatum and also has close relations with the 
thalamus. The cortical, or olfactory, amygdala receives olfactory input directly from the 
olfactory bulb and indirectly from the olfactory cortex. The olfactory amygdala in turn 
projects to the centromedial amygdala and the hypothalamus. The centromedial amygdala 
receives direct input from the cerebral cortex, but is largely restricted to fibers from the 
hippocampal formation, insula, and orbitofrontal cortex. Because the amygdala is a 
bidirectional pathway that can relay information between association cortices and 
subcortical structures it is in an optimal position to simultaneously influence excitability of 
numerous brain regions at any given time [12,13]. 
3. Kindling as a model of brain plasticity 
An excellent model for investigating brain mechanisms associated with neurological and 
neuropsychiatric disorders is kindling. It was Graham Goddard who first acknowledged the 
potential importance of repeated stimulation to the brain as a useful scientific tool. Goddard 
observed that some of his rats began to develop seizures, even with invariant stimulation 
[14]. He and his colleagues studied the phenomenon in more detail [15,16] and subsequently 
referred to the development of stimulation-induced convulsions as “kindling,” analogous to 
starting a fire with an initially benign stimulus [14]. The original kindling work identified 
the amygdala as a critical site due to its reliable and rapid kindling progression. Although 
subsequent research has revealed other salient sites, the amygdala is the most frequently 
targeted structure for kindling studies due to its proximal connections with both cortical 
and subcortical areas.  
In its original description, kindling refers to the progressive development of epileptiform 
activity and associated behavioural convulsions in response to low-intensity electrical 
stimulation of the brain [15,16]. Kindling is generally considered to be the best available 
model of temporal lobe epilepsy and is particularly well suited for experimental study 
because precise control can be implemented over experimental conditions [17]. Progression 
of behavioural and electrographic activity is gradual enough to allow for particular 
manipulation at various phases of the kindling process [18,19]. There are several significant 
characteristics that support kindling’s validity as a clinical model, especially for epilepsy. 
For example, the EEG patterns are similar between the experimental and human conditions, 
the anticonvulsant pharmacology is similar, and the cognitive and behavioural 
abnormalities associated with each condition are also similar [17,20]. These characteristics, 
along with kindling as a model of epilepsy, will be described in more detail below. 
Although most kindling investigations have utilized rats, kindling has been described in 
many other animals, including amphibians, reptiles, mice, gerbils, cats, monkeys, baboons 
[21], and guinea-pigs [3,4,22,23]. It would be surprising to find a phenomenon that bridges 
vertebrates, including amphibians, reptiles, and mammals that would not include humans. 
Indeed, it has also been reported that a human has been kindled [24]. This highlights the 
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applicability of the animal model for humans. Although kindling was originally defined as 
resulting from electrical stimulation, it now collectively refers to the eventual development of 
persistent brain activity following repeated exposure to a stimulus - this can be in the form of 
stimulus trains (electrical activity) or chemical agents. Although kindling is usually employed 
as an experimental model of human temporal lobe epilepsy, kindling in its simplest dimension 
is a model of neural plasticity [14]. In particular, the realization that persistent changes in brain 
function occur in response to an invariant stimulus has led many researchers to believe that 
such mechanisms may be similar to those underlying learning [16,25].  
4. Kindling as a model of neuropsychiatric illness 
As mentioned, kindling is commonly used as a model of epilepsy, but many researchers 
suggest that kindling shows a number of attributes that are similar to neuropsychiatric 
disorders. In particular, kindling is useful in understanding the long-term and developing 
patterns of non-seizure related disorders [26]. Kindling is associated with a progressive 
increase in behavioural and physiological responsivity and a decrease in threshold for an 
event (e.g., a seizure) and can eventually result in a spontaneous event (i.e., spontaneous 
seizure). Because the seizure is used as a convenient endpoint for behavioural and 
physiological responsivity, it is believed that the kindling model can be used to understand the 
progression of various neuropsychiatric disorders [27]. The justification is as follows. The 
disorders are initially expressed with minor behavioural and physiological changes, to more 
complete symptomatology, and then finally to the spontaneous elicitation of the disorder.  
As mentioned previously, the amygdala is a bidirectional pathway that can relay information 
between association cortices and subcortical structures, and is therefore optimally positioned 
to simultaneously influence the excitability of numerous brain regions at any given time. It has 
become increasingly perceptible that structural and functional changes in the amygdala, and 
associated limbic circuitry, are linked to a variety of clinical conditions in humans. It is highly 
conceivable that the amygdala has been connected to various neuropsychiatric and 
neurodevelopmental disorders more than any other brain region. 
The recurrent nature of many neuropsychiatric disorders has been documented for nearly as 
long as the disorders have been investigated [28]. Although it should not be surprising that 
there are many variations within patients, the general course of untreated illnesses tends to 
be predictable. There is a characterization of a diminished healthy period between episodes, 
and a transition from induced events (e.g., personal losses and stressors) to those periods 
that occur more spontaneously. Perhaps the best illustration of this is seen in bipolar 
disorder – minor episodes give way to major episodes. In the beginning there are isolated 
and intermittent events to more continuous rhythmical events, and then to the rapid cycling 
variety [29]. In context of the kindling model, the course of the illness is progressive in that 
there is threshold lowering, and a movement from triggered episodes to spontaneous 
episodes. Stated in a theoretical framework, kindling provides a model for conceptualizing 
physiological and behavioural abnormalities that progress in severity in response to the 
same inducing stimulus over time. 
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In panic disorders, it is apparent that some patients progress from highly intermittent 
attacks that are precipitated by a cue, to those that begin to occur more frequently and 
spontaneously. In addition, some patients become increasingly more paralyzed by 
agoraphobia, which may increase to the point of complete incapacitation. In the case of 
cocaine-related panic attacks, some individuals with a history of anxiety-free episodes with 
repeated administration can suddenly experience a full-blown panic attack. Furthermore, it 
appears that some users can display panic attacks in the absence of continued drug 
administration [30]. Again, it is kindling’s progressive feature with a threshold lowering and 
the move from induced to spontaneous events, that models panic disorder. 
In obsessive compulsive disorder (OCD), initial obsessions and compulsions often increase 
in severity and lead to incapacitation. This progressive nature can be modeled by kindling. 
In post-traumatic stress disorder (PTSD), individuals who have experienced prior traumatic 
events also appear more likely to suffer from PTSD upon repeated exposure to trauma 
[31,32]. Additionally, it appears that repeated inducing events result in more severe and 
long-lasting consequences than isolated events. It appears that there may be a progression in 
the emergence of flashbacks, which are initially triggered by cues linked to the original 
event and occur more spontaneously. The decreases in threshold observed in kindling may 
model greater episode recurrence in this disorder.  
Kindling has also been used to study emotionality [33]. It has been shown that the kindling 
in rats [34] and cats [35] can result in enhanced reactivity and aggressive behaviour. Other 
more enduring behavioural changes that have also been reported following limbic kindling 
have included diminished predatory attack behaviour in cats [36] and decreased ability to 
learn passive avoidance in rats [37]. More recently, it has been reported that repeatedly 
inducing seizures in the amygdala of rats can produce various changes in emotional 
responding, particularly those involving fear and anxiety [38]. 
It may be argued that these neuropsychiatric phenomena are perhaps only analogous, and 
not homologous, to kindling. However, because of many phenomenological similarities, 
kindling may be pertinent to the understanding of the long-term and progressive nature of 
such disorders. 
5. Epilepsy 
The epilepsies comprise a diverse collection of disorders that affect approximately 1% of the 
general population [39]. Epilepsy is a chronic brain disorder, characterized by recurrent 
seizures due to excessive discharge of neurons, with a spectrum of severity ranging from 
mild and benign to severe and intractable. Epilepsy involves a temporary electrical 
disturbance in the brain that can produce effects ranging from momentary loss of 
consciousness to full-blown generalized seizures that involve involuntary jerking of the 
muscles. The various epilepsies affect an estimated 40-50 million people worldwide, 
signifying that epilepsy is a serious neurological disorder and a significant health problem 
in our society. Much of our understanding about epilepsy has come from research on 
animals.  
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Although research has revealed much information about the cellular and synaptic 
mechanisms of seizures and epileptogenesis, many unanswered questions remain. Animal 
models have been and will likely continue to be invaluable for determining the underlying 
mechanisms of the genesis, expression, and propagation of seizures, as well as for the 
screening of new anticonvulsant drugs (ACDs). The identification of new ACDs remains the 
most obvious and important avenue for therapeutic advancement. Because all new ACDs 
are tested on animal models, it seems prudent to test these new drugs on appropriate 
seizure models so as not to discard a potentially valuable drug because it was inadvertently 
tested in an unsuitable model. Accordingly, an important consideration in ACD 
development is the choice of an appropriate animal model for in vivo drug testing [3,4].  
Experimental testing of novel ACDs requires animal models that are predictive in 
anticonvulsant efficacy against specific seizure types and in terms of adverse or toxic effects 
at anticonvulsant doses. Models that mimic the symptoms, natural history, etiology, and 
response to therapy of human seizures are crucial. The most commonly used animal models 
are the maximal electroshock (MES) test and the pentylenetetrazol (PTZ) seizure test. While 
both these models are thought to represent valid models for generalized tonic-clonic (grand 
mal) seizures and generalized absence (petit mal) seizures, respectively [40], they are not 
valid models for partial seizures. Unfortunately the anticonvulsant activity of common 
ACDs in these models are not effective against partial seizures, the most common type of all 
epileptic seizures. Therefore, valid models of partial seizures should be used to test the 
anticonvulsant efficacy against partial epileptic activity [3,4,41].  
As introduced previously, kindling is generally considered to be the best available model of 
human partial epilepsy, and is particularly convenient for experimental study because 
precise control can be implemented over experimental conditions. The progression of 
behavioural and electrographic activity is gradual enough to allow for specific 
manipulations at various phases of the kindling process. There are several significant 
characteristics that support kindling’s validity as a model for partial epilepsy: (1) the EEG 
patterns of hippocampal and amygdala kindled seizures are similar to human complex 
partial seizures; (2) the behaviour associated with initial and later seizures is similar to those 
of human complex partial (limbic or temporal lobe) seizures; (3) the anticonvulsant 
pharmacology of kindled and human partial seizures are markedly similar; (4) the 
occurrence of heterogenous interictal spike transients are common to the kindling model 
and human partial epilepsy; (5) the occurrence of spontaneous seizures in kindled animals; 
(6) kindling can be produced in subhuman primates and kindling-like effects have also been 
observed in humans; and (7) cognitive and behavioural abnormalities have been reported to 
occur in kindled animals and in human epileptics [17,20]. 
Although amygdalar kindling is widely used in rat models, its application to guinea-pig 
models provides a unique vehicle. With its important interconnections, relative ease of 
anatomical location, and reliable epileptiform correlates, the amygdala remains an 
important target for study. With repeated stimulation, guinea-pigs show some initial 
growth of the electrographic indices and behavioural seizures. However, unlike rats, 
guinea-pigs become arrested at partial and complex partial seizures and do not progress to 
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fully generalized convulsions during regular single-site kindling [22,23]. This suggests that 
guinea-pig kindling may be a better model for human complex partial epilepsy because the 
majority of humans with complex partial epilepsy also do not progress to fully generalized 
convulsions. Furthermore, guinea-pig seizures mimic human seizure behaviour and have a 
similar EEG pattern for both ictal and interictal events [3,4].  
Because guinea-pig kindling shares many characteristics with human partial epilepsy it will 
most likely continue to develop as an excellent model of the disorder. Seizures kindled in 
guinea-pigs echo that of human seizure expression, have a similar EEG pattern, display 
more severe seizures when multiple foci are present, and share a close correspondence in 
anticonvulsant pharmacology. Moreover, guinea-pigs slowly manifest seizures and become 
arrested at partial seizures, a consistent observation associated with many species of 
primates [42], including humans [20]. 
The guinea-pig with its sustained period of partial epileptic activity provides certain 
advantages over rats and mice as a model system for human partial epilepsy. There is a 
striking correlation between drugs effective against guinea-pig kindled seizures and drugs 
effective against partial seizures in humans. This correlation strengthens the validity of 
guinea-pig kindling as a model of the human condition, as it seems unlikely that a drug that 
is ineffective against guinea-pig kindled partial seizures will be efficacious against partial 
seizures in humans. Accordingly, examining the efficacy of experimental drugs in this 
model would seem to be a beneficial step before undertaking expensive human clinical 
trials. However, if examination of secondarily generalized seizures was of primary interest, 
then rat kindling would be the preferential model due to their speedy seizure progression 
and development of tonic-clonic seizures.  
Future pharmacological studies should be implemented in the guinea-pig model of partial 
epilepsy to determine the effectiveness of other existing and newer ACDs to further 
elucidate the value of this model for the screening of prospective ACDs. Such studies should 
extend detailed acute and chronic pharmacokinetic analysis to the test drugs in an attempt 
to understand the drug’s absorption and elimination parameters. Concurrent objective 
behavioural assessment should also be carried out to determine potential adverse effects of 
the drugs. While general observation of the animal’s behaviour is important, objective 
quantitative tests allow for greater inter-observer reliability and are potentially more 
sensitive to the behavioural impairment of an ACD. Administration of an ACD requires the 
optimal balance between the anticonvulsant effect and the level of behavioural toxicity. 
Ideally, the more efficacious drugs will have powerful anticonvulsant actions in the absence 
of behavioural impairment. Thus, the sedation and ataxic effects of the test drug need to be 
assessed over multiple doses. It is only with a more in depth inquiry into the underlying 
mechanisms of epilepsy that will prove to be useful in human therapeutic approaches. 
6. Anxiety disorders 
Anxiety is chronic fear that persists in the absence of any direct threat, and is a common 
psychological correlate of stress. When anxiety becomes so disruptive that it interrupts 
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normal functioning, it may manifest as an anxiety disorder. Anxiety disorders are the most 
prevalent of all psychiatric disorders, in that about 17% of people suffer from an anxiety 
disorder at some point in their lives [43,44]. 
The amygdala is known to play an important role in normal fear conditioning and is 
implicated in the pathophysiology of anxiety disorders. The amygdala may also be a target 
for the beneficial effects of cognitive-behavioral and medication treatments for anxiety 
disorders [45]. Animal models have played an important role in the study of anxiety, and in 
the assessment of anxiolytic properties of new psychotherapeutics. Such models typically 
involve animal defensive behaviors, with the assumption that defensive behaviors are 
motivated by fear, where fear and anxiety are identical states. Common models anxiety in 
animals include the elevated-plus maze test, defensive burying, and risk assessment [46].  
In the elevated-plus maze test, rats are placed within a four-armed maze that is raised above 
the floor. Two of the arms have sides, and two do not have sides. The measure of anxiety is 
the proportion of time spent in the enclosed arms versus the time spent in the exposed arms. 
In the defensive-burying test, rats are exposed to a shock apparatus housed at one end of a 
test chamber. Anxiety is measured by the amount of time rats spend spraying bedding 
material towards the source of the shock. In the risk-assessment test, rats are briefly exposed 
to the presence of a cat. They quickly flee to their burrows and freeze, and then engage in a 
variety of risk–assessment behaviors (e.g., cautiously exploring the surface) before their 
normal behavior returns. Anxiety is measured by the amount of time that the rat spends in 
both freezing and in risk assessment behaviors. Note that these anxiety models have 
generally been validated by observation of anxiety reduction through the use of 
benzodiazepines versus non-anxiolytic drugs [47]. 
A primary technique for investigating the mechanisms underlying emotional associative 
learning is Pavlovian conditioning. Studies investigating the neural mechanisms of fear 
conditioning across species indicate that the amygdala has a critical function in the 
acquisition, storage, and expression of conditioned fear [48]. Further, research suggests that 
interaction between the amygdala, the ventromedial prefrontal cortex and the hippocampus 
supports the acquisition, storage, retrieval, and contextual modulation of fear extinction. 
Neuroimaging research has helped to advance neurobiological models of anxiety disorders. 
In individuals with PTSD, research suggests altered emotion neurocircuitry. Emotion 
activation studies in these individuals have shown hyperactivation in emotion-related 
regions, including the amygdala and insula, and hypoactivation in emotion-regulation 
regions, including the medial prefrontal cortex and anterior cingulate cortex. Increased 
connectivity between the amygdala and insula may suggest enhanced anticipation of 
negative events [49]. 
7. Neurodevelopmental disorders 
The amygdala has been implicated in a range of neurodevelopmental disorders. Like our 
entire nervous system, it seems that the amygdala is sensitive to threshold variances. 
Amygdalar dysregulation can result in perceptual changes related to environmental danger 
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and sociality, and thereby result in dysfunctional anxiety. Across a range of studies 
investigating neurodevelopmental disorders, there is evidence of amygdala dysregulation 
from postmortem studies, structural MRI analyses, and functional MRI [50]. 
Schizophrenia is a disorder characterized by deteriorating ability to function in everyday life, 
and includes some combination of hallucinations, delusions, thought disorder, movement 
disorder, and inappropriate emotional expression. It attacks about 1% of individuals of all 
races and cultural groups, typically beginning in adolescence or early adult [43,51].  
Given the substantial contribution of genetic factors to many disease conditions, an obvious 
way of developing animal models would be insertion of human disease–associated alleles 
into mice. Indeed, genetic animal models developed from highly penetrant human 
mutations seem like suitable candidates [52]. However, caution is required as work is 
ongoing to identify which of the genes, or deleted genes, are responsible for the relevant 
behavioral abnormalities in mouse models. While such genetic animal models made with 
variants of small effect may demonstrate interesting neurobiological properties, perhaps it is 
still too early to accept these models as mirroring the etiology of the disease [46]. 
Animal models of maternal infection, or environmental models, have been widely employed 
to look at immune involvement in schizophrenia. For example, prenatal viral infection has 
been used to induce behavioral and neural abnormalities [53], such as the expression of 
immune-related molecules (cytokines) in the brain and cerebral spinal fluid. Perhaps this 
represents a permanent state of brain immune dysregulation which begins during early 
development. Although such results related to immune involvement encourage novel 
therapeutic immune interventions, the role of viral infection in schizophrenia remains unclear.  
Other experimental attempts have used pharmacological manipulations or lesions to 
produce symptoms of schizophrenia. The efficacy of dopamine receptor antagonist drugs in 
treating positive symptoms of schizophrenia gave rise to the deep-rooted dopamine 
hypothesis. Subsequently, the observation that NMDA (n-methyl-d-aspartate) glutamate 
receptor antagonists (e.g., phencyclidine, ketamine) produce psychotic symptoms and 
cognitive disturbances redolent of schizophrenia gave rise to the glutamate hypothesis [54]. 
Consequently, diverse animal models have been based on manipulations of these principal 
transmitter systems, although the putative dopaminergic or glutamatergic abnormalities in 
schizophrenia have not been indubitably established [55]. 
On the basis of evidence obtained from in vivo brain imaging, postmortem, and rodent studies, 
it seems likely that amygdalocortical circuitry has an important function in the pathophysiology 
of schizophrenia. Projections of the basolateral amygdala may be of particular importance to the 
induction of abnormal circuitry in schizophrenia, as their ingrowth during late adolescence and 
early adulthood may help to trigger the onset of illness in susceptible individuals [56]. 
Ultimately then, it seems that abnormalities in limbic lobe components may contribute to a 
dysfunctional regulation of affective responses in schizophrenics.  
Autism is a complex debilitating neurodevelopmental disorder, which involves a wide range 
of problematic behaviours including deficits in language, deficits in perceptual and motor 
development, defective reality testing, and an inability to function in social situations [43]. 
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The amygdala has long been a site of intense interest in the search for neuropathology in the 
brains of people with autism, given its role in modulating anxiety levels and social behavior. 
Schumann et al. [50] conducted a study where autistic adults showed a decrease in neurons 
in the amygdala compared to control groups. It appears that the amygdala undergoes an 
abnormal pattern of postnatal development that includes unusual enlargement, followed by 
a reduction of amygdala size, or decreased neurons, into adulthood.  
Howard et al. [57] found that individuals with high-functioning autism demonstrated 
neuropsychological profiles characteristic of the effects of amygdala damage such as, 
impairment in the recognition of facial expressions of fear, perception of eye-gaze direction, 
and recognition memory for faces. They used MRI analysis techniques to show that the 
same individuals also demonstrated abnormalities of medial temporal lobe brain structure, 
notably bilaterally enlarged amygdala volumes, perhaps reflecting incomplete neuronal 
pruning in early development. These results suggest that developmental malformation of 
the amygdala may underlie the social-cognitive impairments characteristic of autism.  
Other studies have reported that amygdala lesions in isolation are not sufficient for 
producing autistic symptoms. Instead, it may be abnormal connectivity between the 
amygdala and other structures that contributes to autistic symptoms at a network level [58]. 
Dziobek et al. [59] used imaging techniques to measure fusiform gyrus cortical thickness 
and to measure amygdala volumes, and suggest that dysfunction of the amygdalafusiform 
system might represent a crucial pathophysiological mechanism of autism. 
With recent findings linking multiple genes to autism spectrum disorders, novel rodent 
mutants with deletions, truncations, and/or overexpression of these candidate genes have 
been developed and studied both behaviorally and biologically. As the diagnostic criteria 
for autism are behavioural, phenotyping these mouse models requires behavioural assays 
with high relevance to each category of the diagnostic symptoms. These include tests for 
social interaction, communication and repetitive behaviours to test hypotheses about the 
causes of autism. Such mouse models hold great promise as tools for discovering effective 
treatments for components of autism spectrum disorders [60]. 
8. Mood disorders 
Although there a continuum of mood disorders has been identified, the best documented 
ones are depression and mania. The primary symptoms of major depression are prolonged 
feelings of worthlessness and guilt, disruption of normal eating habits, sleep disturbances, a 
general slowing of behavior, and frequent thoughts of suicide. Mania is the polar opposite 
from depression, and is characterized by excessive euphoria. The affected person is typically 
hyperactive and often formulates grandiose plans. The periods of mania often fluctuate into 
states of depression and back again into mania. This condition is referred to as bipolar 
disorder (BD). There is a high incidence of affective disorders in Western societies, with 
about 5% of the population suffering from major depression, and 1-2% suffering from 
bipolar disorder [51,61].  
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Several chronic stress procedures have been employed in various animal models [46]. 
Typically, chronic mild or chronic unpredictable stress involves subjecting normal rodents 
to a series of repeated physical stresses (e.g., restraint, foot shock, cold temperature) over a 
period of weeks. The animals show signs of anhedonia (e.g., reduced sucrose preference), 
which can be reversed by chronic administration of antidepressant medications. Further, 
repeated stress results in hyperexcitability in the basolateral amygdala in rodents [62], 
suggesting a mechanism that might produce pathological amygdala activity in depression. 
Chronic social defeat stress involves subjecting rodents to repeated cycles of social 
subordination, after which the rodents show a range of depression symptom (e.g., 
anhedonia, social withdrawal) which can be reversed by chronic antidepressants [63]. It 
appears that chronic social defeat also induces a metabolic syndrome in mice characterized 
by weight gain, and insulin and leptin resistance, a finding that is consistent with 
homeostatic abnormalities observed in human depression [64]. 
Another model of depression is based on early life stress. Maternal separation in rat pups 
induces life-long behavioral and neuroendocrine abnormalities in the pups, some of which can 
be reversed by antidepressant medications [65]. In addition, it was recently found that 
prolonged exposure (weeks to months) of adult rodents to social isolation induces anhedonia, 
which can also be treated effectively with chronic antidepressant medication [66]. 
Patients with mood disorders manifest abnormalities of morphology in several medial 
prefrontal network and limbic structures. A large body of human data from functional and 
structural imaging, as well as analysis of lesions and histological material indicates that this 
system is centrally involved in mood disorders. Neural models of depression suggest that 
dysfunction within the medial network and related limbic structures underlie the disturbances 
in emotional behavior and other cognitive aspects of the major depressive syndrome [62]. 
The most often used model of mania involves treating normal rodents with 
psychostimulants (e.g., cocaine or amphetamine). The repeated administration of the drugs 
causes sensitization of the acute locomotor-activating effects of the drugs, which in turn can 
be reduced by lithium or valproate, two chief treatments for human bipolar disorder [67]. 
Although these are intriguing findings, caution with this model is warranted. It remains 
unclear that the molecular and cellular changes associated with psychostimulant-induced 
sensitization have direct equivalence with the pathophysiology of bipolar disorder. 
As mentioned previously, chronic stress is known to induce hyperactivation of amygdala, 
enhancing amygdala-dependent unlearned fear, fear conditioning, and aggression. 
Similarly, many of the symptoms experienced by patients with bipolar disorder appear to be 
associated with abnormalities in emotional processing, and an enlargement of the amygdala 
has been described as a prominent abnormality in BD. Abnormal age related increases in the 
amygdala volume have been found in bipolar adolescents. In addition to structural changes 
in this circuitry, functional neuroimaging studies indicate increased activity in the amygdala 
during acute mood episodes [68]. 
Other imaging studies have looked at changes in amygdalar regulation in BD. Bechdolf et al. 
[69] investigated adolescents and young adults with BD prior to the onset of first episode 
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mania. They found that amygdala and insula volume reductions are present prior to the 
onset of first episode mania, a reduction consistent with the amygdala’s central role in 
emotion processing, such as associating stimuli with emotional responses, enhancing 
memory consolidation and influencing perception of stimuli. Another study found 
increased amygdalar activation in BD patients, suggesting an exaggerated response to 
negative emotional stimuli [70]. 
9. Neurodegenerative diseases 
Alzheimer’s disease (AD) is a devastating degenerative brain disorder related to aging that 
first appears as progressive memory loss and later develops into generalized dementia. 
About 10% of the general population over the age of 65 suffers from the disease, and the 
proportion is about 35% in those over 85 [43]. 
AD brains are characterized by the presence of amyloid plaques and neurofibrillary tangles. 
Plaques are clumps of scar tissue composed of degenerating neurons and amyloid protein, 
and the tangles are knots of protein in the cytoplasm. Although plaques and tangles are 
observed throughout the cerebral cortex, they are most prevalent in medial temporal lobe 
structures such as the amygdala, entorhinal cortex, and hippocampus [71]. The amygdala of 
AD patients shows significant shrinkage, distortion and loss of neurons as well as extensive 
gliosis [72,73]. Additionally, the extent of the amygdalar atrophy correlates positively with 
the degree of emotional memory impairment [71]. 
Knafo et al. [74] describes the neuropathological changes in the amygdala and alterations in 
emotional memory of transgenic AD mouse models. They suggest that the morphological 
changes found in the neurons of the lateral nucleus of the amygdala may contribute to the 
impaired auditory fear conditioning observed in this model. Further, they note that AD 
patients also show marked impaired fear conditioning, indicating that deficits in 
nondeclarative memory is common to both AD patients and the transgenic mice. It seems then 
that the behavioral features detected in this AD model are similar to those found in AD. 
Parkinson’s disease (PD) is a disorder of the motor system correlated with the loss of 
dopamine in the brain and characterized by tremors, muscular rigidity, and reduction in 
voluntary movement. Parkinson's disease is a movement disorder of middle and old age 
that affects about .5% of the population [61]. PD is associated with widespread neuronal 
degeneration and the presence of cortical and brainstem Lewy bodies (clumps of proteins). 
Bouchard et al. [75] bolstered evidence for a linkage between PD and volumetric decreases 
in limbic system structures. Through MR imaging, they found specific and predictable 
correlations between the age and sex of a PD patient and the degree of volumetric loss in the 
hippocampus and amygdala.  
Freichel et al. [76] used a transgenic mouse model to assess the behavioral and structural 
implications of mutant α-synuclein (αSYN) expression, a neuronal protein. αSYN inclusions 
constitute the hallmark lesions of a number of neurodegenerative diseases, including PD 
and dementia with Lewy bodies. Using fear conditioning, active avoidance, and water-maze 
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tests, they assessed transgenic mice across a 12 month span for cognitive impairment and 
possible dementia. The mice showed α-synucleinopathy in several brain regions, including 
the central nucleus of the amygdala, which is involved in cognitive behavior of mice, and is 
susceptible to αSYN pathology in human patients.  
In a clinico-pathological study looking at postmortem PD brains, Kalaitzakis et al. [77] 
assessed the correlation between various presentations of PD and specific anatomical and 
pathological correlates, including αSYN, tau, and amyloid deposits in regions associated 
with cognition. They found that the amygdala is specifically burdened with αSYN in cases 
of PD with dementia and also was strongly associated with visual hallucinations. These 
findings support the literature on the phenomenology of hallucinations in 
neurodegenerative diseases and the link between such hallucinations and irregularities in 
the limbic system. 
Huntington's disease (HD) is a rare degenerative disease of the central nervous system that 
affects about .01% of the population. Huntington’s disease is a progressive motor disorder of 
middle to old age, has a strong genetic basis, and is associated with severe dementia [61]. 
The last 10 years or so have seen a significant generation of various transgenic models of 
HD. In particular, a rat model exhibits prominent cellular accumulation of huntingtin, a 
pathological hallmark of HD, in addition to exhibiting ongoing emotional changes [78]. It 
appears that this model will be valuable in interpreting various psychiatric aspects of HD. 
Further, Faure et al. [79] describe emotional blunting and hypersensitivity to negative 
emotional situations in symptomatic transgenic HD, and suggest that some of these symptoms 
may be related to amygdala dysfunction. In particular, they propose that functional alteration 
in brain circuits, with a possible deficit in frontal control, such as shrinkage of the central 
nucleus of the amygdala, may be responsible for these emotional disorders. 
10. Discussion 
Animal research has uncovered considerable information on the cellular and synaptic 
mechanisms of neurological and neuropsychiatric processes, however, many questions 
remain. Unfortunately there is no neuropsychiatric disorder that is effectively understood 
from the level of clinical manifestations to the underlying cellular and molecular 
mechanisms. Given the ethical and practical limitations to human experimental biology and 
neuropsychiatry, animal models will almost certainly be a necessary aspect of progress.  
The development of valid and effective animal models for neurological and neuropsychiatric 
disorders represents a significant challenge. However, despite these challenges, model systems 
are necessary for understanding disease pathophysiology in order to allow for the 
development of appropriate treatments. A good animal model should be able to provide new 
understanding into the disorder it models and respond in a reproducible and predictable 
manner. Other practical characteristics of the model that must be taken into account include 
cost, ease of maintenance, genetic uniformity, and amenability to behavioural testing.  
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Neuroscience has focused significant attention to the amygdala, unmasking its structure, 
function, and physiological mechanisms, across both animals and humans. It has become 
more and more evident that structural and functional changes in the amygdala are 
associated with a wide variety of clinical conditions in humans. Perhaps more than any 
other brain region, the amygdala has been linked to numerous neuropsychiatric, 
neurodevelopmental, and neurological disorders, and therefore a potential target for 
therapeutics to alleviate associated symptoms. The amygdala is an integral part of a neural 
system that evolved early in order to detect environment dangers and modulate subsequent 
responses, a role which can profoundly influence human behavior. Notwithstanding this 
systematic progress, much remains unknown, but the foundational knowledge obtained has 
provided a solid grounding in which to build upon in future work. 
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